Latif, StatPearls , Compare and Contrast the Glucagon-like Peptide-1 Receptor Agonists
See our supplements evidence guide
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency
In 1963 Samols and Marks published the first paper setting out the case for using RIA insulin measurements for the clinical evaluation of cases of hypoglycemia
There are thyroid concerns, with animal studies showing thyroid C-cell tumors, though human relevance remains unclear
This article is part of the PlexusDx Education Hub practical, evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic factors behind every metabolic decision